Video -- Matastasectomy: Does it make sense in the setting of effective systemic therapy?

I found this video presentation from Dr. Argarwala's 2013 HemOnc Today Melanoma Conference this past March in New York interesting: Matastasectomy: Does it make sense in the setting of effective systemic therapy? by Moffitt Cancer Center's Dr. Vernon Sondak. Provectus some time back had initially facilitated my ability to communicate and interact with Dr. Sondak.

In the presentation, he contrasts and compares surgery PFS and survival times and their respective percentages (PFS6, OS12) to results of various systemic treatment therapies.

Intralesional therapy like PV-10 is the best treatment option for patients who are not amenable to surgery. There undoubtedly will be interest in the pre-operative use of intralesional therapy, but traditional thinking suggests such interest would be on a research basis for the foreseeable future. 

Surgical oncologists, however, including several key opinion leaders, think intralesional therapy PV-10 already is viable for pre-operative use, whether the patient is or is not amenable to surgery.